JointHealth
français
 
JointHealth™ express   December 10, 2013


Last chance to complete SEB survey for Ontario!

On November 8, Arthritis Consumer Experts (ACE) asked for your views on subsequent-entry biologics (SEBs). Health Canada defines SEBS as a “biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug.” Unlike generic medications, SEBs are not identical to their originator drugs. Since every biologic is made from living cells, even minor differences from the originator drug change the way a SEB acts in the body.

Today is the last day to complete this short survey to let us know how much you know about SEBs. Your feedback is vitally important to the work ACE conducts on behalf of the more than 1.8 million people in Ontario living with arthritis.

Please be assured that all responses will remain anonymous and confidential. Personal information will not be collected as part of this survey.